Multiple angiogenesis stimulators in a single malignancy: Implications for anti-angiogenic tumour therapy

Anti-angiogenesis is likely to develop into a novel therapeutic approach for patients with solid malignancies. Most current clinical trials evaluate anti-angiogenic drugs aimed primarily against single angiogenesis stimulators. Here, we show that a single solid malignancy, i.e., a human embryonal rh...

Full description

Saved in:
Bibliographic Details
Published in:Angiogenesis (London) 2001, Vol.4 (4), p.259-262
Main Authors: PAVLAKOVIC, Helena, HAVERS, Werner, SCHWEIGERER, Lothar
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - therapeutic use
Animals
Antineoplastic agents
Biological and medical sciences
Cattle
Chemotherapy
Chromatography, Affinity
Endothelial Growth Factors - metabolism
Endothelial Growth Factors - physiology
Endothelium, Vascular - cytology
Enzyme-Linked Immunosorbent Assay
Fibroblast Growth Factor 2 - metabolism
Fibroblast Growth Factor 2 - physiology
Humans
Interleukin-8 - metabolism
Interleukin-8 - physiology
Lymphokines - metabolism
Lymphokines - physiology
Medical sciences
Neovascularization, Pathologic
Pharmacology. Drug treatments
Urinary Bladder Neoplasms - blood supply
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-angiogenesis is likely to develop into a novel therapeutic approach for patients with solid malignancies. Most current clinical trials evaluate anti-angiogenic drugs aimed primarily against single angiogenesis stimulators. Here, we show that a single solid malignancy, i.e., a human embryonal rhabdomyosarcoma, produces in vivo at least three biologically active angiogenesis stimulators (vascular endothelial growth factor, basic fibroblast growth factor and interleukin-8). This suggests that tumour angiogenesis results from the activity of multiple, rather than a single angiogenesis stimulator(s). We, furthermore, show that a combination of anti-angiogenic drugs is more effective in inhibiting tumour-induced endothelial cell growth than a single agent. Our results imply that clinical anti-angiogenic strategies for the treatment of solid malignancies may be most effective when multiple rather than single antiangiogenic drugs are used.
ISSN:0969-6970
1573-7209
DOI:10.1023/A:1016045012466